Peroxisome proliferator activated receptor-c (PPARc) regulates metabolic homeostasis and adipocyte differentiation, and it is activated by oxidized and nitrated fatty acids. Here we report the crystal structure of the PPARc ligand binding domain bound to nitrated linoleic acid, a potent endogenous ligand of PPARc. Structural and functional studies of receptor-ligand interactions reveal the molecular basis of PPARc discrimination of various naturally occurring fatty acid derivatives.
Peroxisome proliferator activated receptor-c (PPARc) regulates metabolic homeostasis and adipocyte differentiation, and it is activated by oxidized and nitrated fatty acids. Here we report the crystal structure of the PPARc ligand binding domain bound to nitrated linoleic acid, a potent endogenous ligand of PPARc. Structural and functional studies of receptor-ligand interactions reveal the molecular basis of PPARc discrimination of various naturally occurring fatty acid derivatives.
PPARg is a nuclear receptor that regulates adipocyte differentiation and glucose homeostasis 1 . The synthetic PPARg ligands rosiglitazone (Avandia) and pioglitazone (Actos) are thiazolidinedione derivatives (TZDs) used for the treatment of type 2 diabetes. Despite the importance of PPARg in human physiology and drug discovery, the identity of physiological ligands remains elusive. The first implicated natural ligand of PPARg was 15-deoxy-D 12,14 -prostaglandin J 2 (PGJ 2 ), an oxidized fatty acid 2, 3 . Later, 9-hydroxyoctadecadienoic acid (9-HODE) and 13-hydroxyoctadecadienoic acid (13-HODE), two oxidized fatty acids present in oxidized low-density lipoprotein, were shown to activate PPARg in macrophages 4 . Despite the low receptor affinity of these oxidized fatty acids, they are more potent than native fatty acid counterparts. Recent studies provide functional evidence that nitrated linoleic acid (LNO 2 ) and nitrated oleic acid (OA-NO 2 ) potently activate PPARg at nanomolar concentrations [5] [6] [7] , with net concentrations of nitrated fatty acid species exceeding 1 mM in human plasma lipids, supporting the idea that nitrated fatty acids are high-affinity, endogenous PPARg ligands. This is also relevant to clinical therapeutics, as PPARg, lipid and nitric oxide signaling pathways have been implicated in diabetes, obesity and cardiovascular diseases 8, 9 . Moreover, nitric oxide-mediated oxidative and nitrative reactions induce fatty acid nitration, thus representing a convergence of lipid and nitric oxide-mediated signaling. The discovery of nitrated fatty acids as potent PPARg ligands suggests further functional linkages between these seemingly disparate signaling pathways. The inactivity of linoleic acid as a PPARg ligand 4 raises questions as to why the oxidation and nitration of linoleic acid can yield much more potent PPAR activators.
Although TZDs improve insulin sensitivity and lower plasma glucose levels, they have adverse side effects, including weight gain, fluid retention and hepatotoxicity 10 . In addition, the recently identified cardiovascular risks of rosiglitazone 11 may jeopardize further development and clinical application of TZD-based PPARg ligands. A drug-design strategy based on endogenous PPARg ligands may yield more efficacious PPARg-targeted drugs, but little is known about how PPARg interacts with natural ligands such as LNO 2 .
To unravel the biochemical mechanism of human PPARg activation by nitrated fatty acids, we determined the ability of LNO 2 to promote recruitment of coactivator LXXLL motifs by PPARg using the AlphaScreen biochemical assay 12 (Supplementary Methods online). Both LNO 2 and rosiglitazone strongly enhanced the interaction of PPARg with various coactivator LXXLL motifs from the family of steroid receptor coactivators (SRC2-3 and SRC1-2), CREB binding protein (CBP), TRAP220 and PGC-1a, indicating that LNO 2 functions as a PPARg agonist ( Supplementary Fig. 1a online) . Similarly to rosiglitazone, LNO 2 also potently promoted the interaction of PPARg with coactivator motifs in a concentration-dependent manner ( Supplementary Fig. 1b,c) . PPARg showed only weak interaction with coactivators upon addition of 20 mM of either 9-HODE or PPARg. PPARg is in green, the SRC1-2 peptide is in yellow and the bound LNO 2 is shown in stick representation with carbon, nitrogen and oxygen atoms depicted in pink, blue and red, respectively. Fig. 1a ), in agreement with their in vivo effects 4 . These results reaffirm that nitrated fatty acids are potent PPARg ligands.
13-HODE (Supplementary
To determine the molecular basis of the high-affinity binding of LNO 2 by PPARg, we solved the crystal structure of PPARg complexed with LNO 2 and the SRC1-2 LXXLL motif at 2.4 Å -resolution (Supplementary Table 1 online). The PPARg ligand binding domain (LBD) forms a dimer, with helix 10 from each monomer forming a dimer interface that resembles that of the PPARg-RXRa heterodimer complex 13 (Fig. 1a) . The binding mode of LNO 2 is similar to that of rosiglitazone, with one LNO 2 molecule occupying roughly 40% of the ligand binding pocket (Fig. 1b) . The existence of two distinct C10 and C12 LNO 2 regioisomers in the PPARg pocket was apparent from the highly revealing electron density map (Fig. 2) . The acidic head group of both LNO 2 isomers forms several hydrogen bonds with the surrounding PPARg residues, including Gln286 from helix 3 ( Fig. 2a) . These interactions are observed for both LNO 2 and rosiglitazone, and they support a crucial conserved mechanism for ligand-mediated activation of PPARg. Indeed, the Q286A mutation that disrupts these interactions decreased the activation of PPARg by both LNO 2 and rosiglitazone in cell-based assays using a PPARgresponse reporter (Fig. 3) .
The selectivity of PPARg for binding LNO 2 is explained by the specific interactions of the two nitro groups with the PPARg pocket residues (Fig. 3a) . The C10 nitro group forms a hydrogen bond with Arg288, and the C12 nitro group interacts with Glu343 ( Fig. 2b) . Mutation of either residue decreased PPARg activation by LNO 2 but had no effect on PPARg activation by rosiglitazone (Fig. 3b) , suggesting that nitro group interactions with Arg288 and Glu343 are required for stable binding of LNO 2 . Notably, modeling studies indicate that the hydroxyl group in 9-HODE and 13-HODE occupies the same position as the nitro groups of the two LNO 2 isomers ( Supplementary  Fig. 2a,b online), suggesting that these hydrogen-bond interactions should be preserved in the complex between PPARg and these oxidized fatty acid regioisomers. Notably, the R288H mutation detected in colon cancers induced decreased binding of PGJ 2 (ref. 14) . Furthermore, the Arg288 residue has been implicated in the binding of the endogenous PPARg ligand alkylglycerophosphate (AGP) 15 . Together, these data help to explain why PPARg binds nitrated and oxidized linoleic acid but not unmodified linoleic acid 4, 5 .
To further validate the specific impact of charged residues on PPARg-LNO 2 binding, we mutated several hydrophobic residues to arginine in the ligand binding pocket surrounding the nitro groups. These mutations should favor hydrogen bonding between the PPARg pocket residues and the bound LNO 2 . Accordingly, all these mutations substantially increased PPARg activation by LNO 2 but not by rosiglitazone (Fig. 3b) . The binding of LNO 2 is further facilitated by the two cis double bonds of LNO 2, which introduce a 901 bend around the C9 to C13 position that allows the rest of the hydrocarbon chain to fit into a hydrophobic pocket of PPARg (Fig. 2a) . Conformational changes in two pocket residues (Glu343 and Phe287) are evidenced when the LNO 2 -PPARg complex is overlaid on the rosiglitazone-PPARg structure ( Fig. 2c,d) . In response to LNO 2 binding, the charged side chain of Glu343 adopts a second conformation, allowing the receptor to form a hydrogen bond with the nitro group. The hydrophobic side chain of Phe287 also shifts from its rosiglitazone-bound conformation toward the hydrophobic tail (C18) of LNO 2 , thus stabilizing LNO 2 binding by making additional hydrophobic interactions with the LNO 2 backbone. To validate the differential roles of Phe287 and Glu343 in binding to rosiglitazone versus LNO 2 , we determined the in vitro ligand binding properties of PPARg mutants using Alpha-Screen assays ( Supplementary Fig. 3 online) . The binding potency of LNO 2 was decreased by both mutations, whereas the binding potency of rosiglitazone was not affected. Mutations in Phe287 or Glu343 also reduced the activation of PPARg by LNO 2 but not by rosiglitazone in cell-based assays, further affirming that these interactions are specific for LNO 2 (Fig. 3b) .
The three PPAR subtypes (a, b/d and g) are characterized as fatty acid receptors with distinct selectivity for ligands 2, 3, 16 . PPARg has a preference for unsaturated or hydrophilic fatty acids, whereas PPARa can also bind saturated fatty acids 16 . Together with the structure of PPARb/d-bound eicosapentaenoic acid, the structure of LNO 2 bound to PPARg presented herein reveals a molecular basis for PPAR selectivity toward various fatty acids. Despite the high degree of homology among the three PPARs, the charged residues Arg288 and Glu343 of PPARg, which make specific contacts with the nitro groups, are not conserved ( Supplementary Fig. 2c) , indicating that the PPARg ligand binding pocket has unique hydrophilic properties that dictate the discrimination of native fatty acids and those modified by oxidation and nitration reactions.
The specific interactions between crucial LBD residues of PPARg and LNO 2 thus provide an important perspective regarding the recognition of nitrated and oxidized fatty acids by PPARg. On the basis of the above structural observations, PPARg contains two electrostatic binding epitopes: one epitope, in part comprising the C-terminal activation helix (AF2, Fig. 1b) , is common for binding of the acidic group of LNO 2 and TZDs; the other epitope, comprising Arg288 and Glu343, is specific for the nitrated or oxidized groups of modified fatty acids. The differential binding modes of endogenous ligand versus the therapeutic drug rosiglitazone may allow the differential modulation of PPARg ligand binding selectivity and affinity, thereby affecting the physiological outcome of different PPARg ligands. As such, the structural mechanism may provide a more rational template for designing PPARg ligands that would better mimic nitro group-receptor interactions by the endogenous PPARg ligand LNO 2 . On the basis of the structural insight into LNO 2 -PPARg interactions gained herein, we expect that new compounds can be developed that have a more favorable pharmacological impact than current TZD-based synthetic PPARg ligands.
Accession code. Protein Data Bank: Coordinates for PPARg-LNO 2 have been deposited with accession code 3CWD.
Note: Supplementary information is available on the Nature Structural & Molecular Biology website.
